Imagenetix, Inc. Announces Interview With Bloomberg Radio

Imagenetix, Inc. Announces Interview With Bloomberg Radio

* Director of Research and Development, Dr. Robert Hesslink, Discusses Science Behind Innovative Compounds and Products at Canaccord Adams Global Growth Conference

SAN DIEGO, Aug. 17 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), an innovator of scientifically tested, natural-based, proprietary products announced that last week Dr. Robert Hesslink, Director of Research & Development, was interviewed by Pimm Fox on his Bloomberg Radio program, Taking Stock. Dr. Hesslink discussed the bioceutical business of Imagenetix outlining the science behind its flagship product, InflameAway Celadrin , and 1-TDC, Imagenetix's early stage drug candidate for periodontal disease.

Dr. Hesslink, stated, "We had just announced publication of our second study on 1-TDC in the Journal of Periodontology so the timing of the interview was ideal."

The recent study on 1-TDC was conducted at Boston University Department of Periodontology and Oral Biology. The study results show that 1-TDC stopped the progression of periodontal disease with a significant improvement and restoration of tissue and bone health compared to the placebo group. The study was published in the July issue of The Journal of Periodontology and is also available online at: http://www.joponline.org/loi/jop (J Periodontal 2009; 80(7):1103-13).

To listen to the Bloomberg Radio interview, please follow this link: www.larrychendesign.com/iagxinterview.html

About Imagenetix

Imagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis. Imagenetix develops and formulates propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Inflame Away -Celadrin . Please visit, www.celadrin.com or www.imagenetix.net.

Certain matters in this news release are forward-looking statements which are subject to risks and uncertainties that could cause actual results to vary materially from those projected. Such risks and uncertainties include, but are not limited to, adverse fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in the company's SEC filings, including its Form 10-K for the year ended March 31, 2009.

Contact Imagenetix Investor Relations William P. Spencer
(858)385-2797 Chief Executive Officer
Imagenetix, Inc.
Tel: (858) 674-8455

Source: Imagenetix, Inc.

CONTACT: Imagenetix Investor Relations, +1-858-385-2797, or William P.
Spencer, Chief Executive Officer of Imagenetix, Inc., +1-858-674-8455

Web Site: http://www.imagenetix.net/
http://www.celadrin.com/

-------
Profile: intent